Predictive Markers and Targeted Therapies in Gastroesophageal Cancer (GEC)-Reference-Cited by-同舟云学术

Predictive Markers and Targeted Therapies in Gastroesophageal Cancer (GEC)

Published:2018-12-07 Issue: Volume: Page:431-435
ISSN:
Container-title:Predictive Biomarkers in Oncology
language:
Short-container-title:

Author:

Rüschoff Josef

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-319-95228-4_39

Reference18 articles.

1. World Cancer Research Fund International. Stomach cancer statistics. Retrieved from: http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/stomach-cancer-statistics .

2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

3. Lorenzen S, Riera Knorrenschild J, Haag GM, et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer. 2015;51:569–76.

4. Tabernero J, Hoff P, Shen L, et al. Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): final analysis of a phase III study (JACOB). Ann Oncol. 2017;28(suppl_5):v209–68.

5. Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18:640–53.